Trial reportPituitary2014
Second attempt to withdraw cabergoline in prolactinomas: a pilot study.
Trial report in Pituitary, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis.Endocrine · 2018Pooled it
- Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.Pituitary · 2015Pooled it
- Predictors of favorable long-term outcomes in first-line surgery for microprolactinomas.Journal of neuro-oncology · 2025Article
- Cystic versus non-cystic prolactinoma: clinical, hormonal, radiological, and remission outcomes in Basrah.Frontiers in endocrinology · 2025Article
- Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center.Journal of endocrinological investigation · 2024Article
- Treatment of hyperprolactinemia in women: A Position Statement from the Brazilian Federation of Gynecology and Obstetrics Associations (Febrasgo) and the Brazilian Society of Endocrinology and Metabolism (SBEM).Archives of endocrinology and metabolism · 2024Article
- Hyperprolactinemia in women: treatment.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2024Article
- Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.Nature reviews. Endocrinology · 2023Review
- Approach to the Patient With Prolactinoma.The Journal of clinical endocrinology and metabolism · 2023Review
- Prolactinomas in adolescent and elderly patients-A comparative long-term analysis.Frontiers in surgery · 2023Article
- Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors.European journal of endocrinology · 2022Article
- Machine Learning for Outcome Prediction in First-Line Surgery of Prolactinomas.Frontiers in endocrinology · 2022Article
- First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.Journal of endocrinological investigation · 2021Article
- Long-term IGF-1 monitoring in prolactinoma patients treated with cabergoline might not be indicated.Endocrine · 2021Article
- Commentary: "Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery".Frontiers in endocrinology · 2021Article
- High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?Endocrine · 2020Article
- Dopamine agonists in prolactinomas: when to withdraw?Pituitary · 2020Review
- Dopamine agonist withdrawal in hyperprolactinemia: when and how.Endocrine · 2018Article
- Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?Pituitary · 2016Observational
- Second Attempt of Cabergoline Withdrawal in Patients with Prolactinomas after a Failed First Attempt: Is it Worthwhile?Frontiers in endocrinology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAccording to Pituitary and Endocrine Society recommendations, cabergoline (CAB) therapy can be discontinued after 2 years in hyperprolactinemic patients who fit certain criteria. Previous studies found recurrence rates ranging between 26 and 69 %. Whether CAB therapy can be successfully discontinued after one unsuccessful withdrawal is unknown.
methodsWe conducted a pilot prospective two-center study on a second attempt of CAB withdrawal. Inclusion criteria were: (1) recurrence of hyperprolactinemia after first withdrawal; (2) additional CAB therapy for at least 2 years; (3) normal serum prolactin; (4) CAB dose ≤ 1 mg/week. Prolactin level was monitored after discontinuing therapy. Median follow up for patients who are still in remission was 42 months (range = 24-60).
resultsA total of 17 patients were recruited. Mean age was 41.0 ± 17.3 years. 65 % were female. Initial tumors were microadenoma in 64.7 %, and macroadenoma in 35.3 %. The average weekly CAB dose at second withdrawal was 0.38 ± 0.20 mg (median = 0.25, range = 0.175-1). Eleven of 17 patients (64.7 %) recurred. Median time to recurrence was 6 months. The incidence of recurrence was 44 events per 100 person-years. The estimated cumulative hazard of recurrence was 40 and 82 % at 6 and 12 months respectively. The probability to be recurrence-free at 6 and 12 months was 65 and 41 %, respectively.
conclusionsSecond attempt of CAB withdrawal after 2 additional years of therapy may be successful in some patients. A second withdrawal can be attempted with close monitoring of prolactin level. In this study, we could not identify any predictor of recurrence. Most of the recurrences occurred within the first 12 months after withdrawal.
Indexed as
Identifiers
24078319What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.